UBS analyst Michael Yee upgraded Biogen (NASDAQ: BIIB) from Neutral to Buy with a price target of $225.00 (from $185.00).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Upgrades